Oncimmune Holdings plc (ONC.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
MediCity
Nottingham, NG90 6BH
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1157 840 500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
40
First IPO Date
May 18, 2016
| Name | Title | Pay | Year Born |
| Martin John Gouldstone | Chief Executive Officer & Director | 255,000 | 1966 |
| Martin Hudson | Chief Financial Officer | 0 | N/A |
| Cléa Rosenfeld | Head of Investor Relations | 0 | N/A |
| Petra Budde | Chief Scientific Officer | 0 | N/A |
Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.